About
Alopexx, Inc.
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).
To date over 75 separate pathogens have been found to express PNAG.
While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections.
In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed.
Alopexx, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Daniel R Vlock, MD
President, Chief Executive Officer and Director
Thomas T. Thomas
Chief Financial Officer
Gerald B. Pier, PhD
Chief Scientific Officer
William W. Chin, MD
Senior Strategic Advisor, Director
Christine de los Reyes, PharmD, MBA
Chief Business Officer, Chief Commercialization Officer
Peter J. Werth
Director
